PE20190475A1 - Inhibidores de cdk2/4/6 - Google Patents
Inhibidores de cdk2/4/6Info
- Publication number
- PE20190475A1 PE20190475A1 PE2019000359A PE2019000359A PE20190475A1 PE 20190475 A1 PE20190475 A1 PE 20190475A1 PE 2019000359 A PE2019000359 A PE 2019000359A PE 2019000359 A PE2019000359 A PE 2019000359A PE 20190475 A1 PE20190475 A1 PE 20190475A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- fluoroalkyl
- cdk2
- compounds
- pyrimidin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a compuestos de las formulas (I) o una sal farmaceuticamente aceptable del mismo, en donde: R1 es heterociclilo de 3 a 10 miembros sustituido; R2 es independientemente F, OH, alquilo de C1-C4, entre otros; R3 es H, F, Cl, NH2, alquilo de C1-C4 o fluoroalquilo de C1-C4, en donde el alquilo de C1-C4 y fluoroalquilo de C1-C4 se sustituyen opcionalemente por OH; CN, alcoxi de C1-C4, entre otros; R4 es H, alquilo de C1-C2 o fluoroalquilo de C1-C2; R2A y R2B son independientemente H, OH o alquilo de C1-C4; p es 0,1, 2, 3 o 4; q es 0,1, 2 o 3; r es 0, 1 o 2. Son compuestos preferidos 8-ciclopentil-2-{[1-(metilsulfonil) piperidin-4-il] amino}pirido[2,3-d]pirimidin-7(8H)-ona; 4-({6-(2-hidroxietil)-8-[(1R,2S)-2-metilciclopentil]-7-oxo-7,8-dihidropirido[2,3-d]pirimidin-2-il}amino)-N-metilpiperidin-1-sulfonamida. Dichos compuestos pueden inhibir la actividad de CDK2, incluyendo CDK2, CDK4 y/o CDK6. Tambien se refiere a una composicion farmaceutica que es util para el tratamiento de crecimiento celular anormal, en particular el cancer de mama y ovario.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662371602P | 2016-08-15 | 2016-08-15 | |
US201762533347P | 2017-07-17 | 2017-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190475A1 true PE20190475A1 (es) | 2019-04-04 |
Family
ID=59631834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000359A PE20190475A1 (es) | 2016-08-15 | 2017-07-31 | Inhibidores de cdk2/4/6 |
Country Status (41)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20190062A (es) * | 2016-08-15 | 2019-05-22 | Pfizer | Inhibidores de cdk2/4/6 |
JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
JP2020097562A (ja) * | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド[2,3−d]ピリミジン−7(8h)−オンの合成 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
EP3911650A1 (en) | 2019-01-17 | 2021-11-24 | Pfizer Inc. | Crystalline form of a cdk inhibitor |
MX2021009682A (es) * | 2019-02-15 | 2021-11-12 | Incyte Corp | Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos. |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
KR20220003565A (ko) * | 2019-04-19 | 2022-01-10 | 화이자 인코포레이티드 | Pah를 치료하기 위한 항증식제 |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
EP3976090A1 (en) | 2019-05-24 | 2022-04-06 | Pfizer Inc. | Combination therapies using cdk inhibitors |
WO2020240360A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
WO2021072232A1 (en) * | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
JP2023501110A (ja) * | 2019-10-17 | 2023-01-18 | シーセン ファーマシューティカル カンパニー リミテッド | Cdk2/4/6三重阻害剤としてのアミノピリミジン化合物 |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
CN115551856A (zh) * | 2020-02-28 | 2022-12-30 | 重庆复尚源创医药技术有限公司 | 作为cdk2/4/6抑制剂的化合物 |
TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2(cdk2)高选择性氘代抑制剂 |
CN115702155A (zh) * | 2020-06-17 | 2023-02-14 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 |
WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
US20230357211A1 (en) | 2020-09-15 | 2023-11-09 | Pfizer Inc. | Solid forms of a cdk4 inhibitor |
AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
IL303661A (en) * | 2020-12-22 | 2023-08-01 | Nikang Therapeutics Inc | COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY |
WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
WO2022152259A1 (zh) * | 2021-01-15 | 2022-07-21 | 江苏先声药业有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
TWI823420B (zh) * | 2021-06-09 | 2023-11-21 | 大陸商鄭州同源康醫藥有限公司 | 用作cdk激酶抑制劑的化合物及其應用 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
CN116390921A (zh) * | 2021-09-29 | 2023-07-04 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
CA3238551A1 (en) * | 2021-11-18 | 2023-05-25 | Steven FRUCHTMAN | Methods and compositions for treating cancer |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
WO2023249968A1 (en) * | 2022-06-22 | 2023-12-28 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
US20240174665A1 (en) * | 2022-08-19 | 2024-05-30 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
EP0946554A1 (en) | 1996-11-27 | 1999-10-06 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
AU749750B2 (en) | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
JP2003523358A (ja) * | 2000-01-27 | 2003-08-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 神経変性疾患の治療のためのピリドピリミジノン誘導体 |
AP2002002643A0 (en) | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
DK1361880T3 (da) | 2001-02-12 | 2006-01-23 | Hoffmann La Roche | 6-substituerede pyrido-pyrimidiner |
KR20060111716A (ko) * | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 |
US7196090B2 (en) * | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
EP1648889B1 (en) | 2003-07-11 | 2008-10-29 | Warner-Lambert Company LLC | Isethionate salt of a selective cdk4 inhibitor |
CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
CN102746298A (zh) * | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
US8044062B2 (en) * | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
RU2009108006A (ru) | 2006-09-08 | 2010-10-20 | Пфайзер Продактс Инк. (Us) | Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов |
KR101099926B1 (ko) * | 2006-09-15 | 2011-12-28 | 화이자 프로덕츠 인코포레이티드 | 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도 |
EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
WO2008124161A1 (en) * | 2007-04-10 | 2008-10-16 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
CN102015704A (zh) * | 2008-04-29 | 2011-04-13 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
CN102177161A (zh) | 2008-10-22 | 2011-09-07 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
JP2014513079A (ja) * | 2011-04-08 | 2014-05-29 | アフラクシス・ホールディングス・インコーポレイテッド | 神経系疾患及び癌の治療のための8−エチル−6−(アリール)ピリド[2,3−d]ピリミジン−7(8h)−オン |
KR20140040726A (ko) * | 2011-04-29 | 2014-04-03 | 엑셀리시스, 인코포레이티드 | PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 |
TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
JP2015511245A (ja) * | 2012-02-23 | 2015-04-16 | アッヴィ・インコーポレイテッド | ピリドピリミジノン系キナーゼ阻害薬 |
DK2958916T3 (en) | 2013-02-21 | 2018-11-12 | Pfizer | Solid forms of a selective CDK4 / 6 inhibitor |
US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US20160304466A1 (en) * | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
US9760610B2 (en) | 2014-07-31 | 2017-09-12 | Linkedin Corporation | Personalized search using searcher features |
CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
CR20190062A (es) * | 2016-08-15 | 2019-05-22 | Pfizer | Inhibidores de cdk2/4/6 |
-
2017
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en active Application Filing
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko active IP Right Grant
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 MX MX2019001849A patent/MX2019001849A/es unknown
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 CN CN202210092651.2A patent/CN114394966A/zh active Pending
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-01 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
NI202000072A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
UY38553A (es) | Inhibidores de cdk2 | |
PE20140970A1 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
AR089641A1 (es) | COMPUESTOS BICICLICOS Y SUS USOS COMO INHIBIDORES DUALES DE c-SRC/JAK | |
PE20240584A1 (es) | Agonistas del receptor de glp-1 y usos de los mismos | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
PE20080263A1 (es) | Compuestos de pirrolo-pirimidina y sus usos | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
CL2017001422A1 (es) | Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas | |
PE20120506A1 (es) | Derivados de pirazolopiridina como inhibidores de quinasas | |
PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
PE20160588A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
PE20140250A1 (es) | Derivados de piperidina puenteada | |
AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
UY28578A1 (es) | Derivados de amida | |
PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
CO6630133A2 (es) | Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso | |
AR046119A1 (es) | Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y / o vegf su preparacion y sus usos como medicamento | |
UY29301A1 (es) | Derivados amida |